CAR T cells for advanced osteosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether specially engineered immune cells (called CAR T cells) can attack and kill osteosarcoma tumors that have not responded to standard treatments. It may be an option for children and adults whose cancer has returned or is not controlled by chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be at least 1 year old and up to 75 years old.
- The cancer must be confirmed as osteosarcoma (a type of bone cancer).
- You must have had treatment with a type of chemotherapy called anthracycline, or be unable to receive it.
- Your cancer must have grown or spread within the last 6 months, or you must have new tumors visible on scans.
- You must stop most other cancer treatments at least 7 days before starting the trial (some need longer breaks).
- Your organs (kidney, liver, lungs, heart) and blood cell counts must be working well enough as shown by tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (called C7R-GD2 CAR-T cells) that are trained to find and kill cancer cells. It's for children and young adults with osteosarcoma or neuroblastoma that has not gotten better with standard treatments.
This trial tests a special immune cell treatment (CAR T cells) that target a protein called FOLR1 found on some AML cells. It is for children aged 6 or younger whose leukemia has come back or not responded to treatment.
This trial tests a new kind of immunotherapy for children and teens with solid tumors that have not responded to standard treatments. The therapy uses specially engineered T cells (CAR T cells) that target a protein called GPC3 found on many tumor cells, and it includes extra signals (IL-15 and IL-21) to help the T cells work better.
This trial tests a new type of cell therapy called B7-H3 CAR T cells for children and young adults with high-risk osteosarcoma that hasn't spread or worsened after standard chemotherapy. The treatment uses your own immune cells that are modified to attack a protein (B7-H3) found on cancer cells.
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
This trial tests a new type of immunotherapy where your own immune cells are modified to find and attack sarcoma cells that carry markers called CD146 or HER2. It is for people with advanced sarcoma who have already tried standard treatments.
Hear when a new Recurrent Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.